MeiraGTx HoldingsFRA:328 +6.00%55 Days Payable is 6,138.03 as of Mar. 2026, which is 681% above its 10-year median of 786.06. GuruFocus rates FRA:328 with a GF Score™ of 55/100 and a GF Value™ of €20.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 705 Biotechnology companies, MeiraGTx Holdings ranks better than 89.79% on this metric.
The historical rank and industry rank for MeiraGTx Holdings's Days Payable or its related term are showing as below:
FRA:328'
s Days Payable Range Over the Past 10 Years
Min: 303.99 Med: 786.06 Max: 1876.06
Current: 1876.06
During the past 10 years, MeiraGTx Holdings's highest Days Payable was 1876.06. The lowest was 303.99. And the median was 786.06.
FRA:328's Days Payable is ranked better than 89.79% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs FRA:328: 1876.06
MeiraGTx Holdings's Days Payable
increased
from Mar. 2025 (1,477.64) to Mar. 2026 (6,138.03).
It may suggest that MeiraGTx Holdingsdelayed paying its suppliers.
MeiraGTx Holdings Days Payable Related Terms
MeiraGTx Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:328 vs XNCR, WVE, CGEM: Days Payable Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MeiraGTx Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (FRA:328) has a Days Payable of 6,138.03 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MeiraGTx Holdings and its competitors. This is 681% above median its historical median of 786.06. Over the past decade, MeiraGTx Holdings' Days Payable has ranged from 303.99 to 1,876.06. According to the industry distribution chart, MeiraGTx Holdings ranks #72 out of 705 companies in the Biotechnology industry, placing it in the top 10.2%.
Is MeiraGTx Holdings' Days Payable too high?
MeiraGTx Holdings' current Days Payable of 6,138.03 is 681% above median its 10-year median of 786.06. Over the past 10 years, this metric has ranged from a low of 303.99 to a high of 1,876.06. The Biotechnology industry median Days Payable is 113.36. MeiraGTx Holdings' value of 6,138.03 is 5314.6% above this industry median. Based on the distribution chart, MeiraGTx Holdings ranks #72 out of 705 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Days Payable compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #72 out of 705 companies for Days Payable. This places MeiraGTx Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. MeiraGTx Holdings' value of 6,138.03 is 5314.6% above this benchmark. Historically, MeiraGTx Holdings' own Days Payable has ranged from 303.99 to 1,876.06 over the past decade. While the company's 10-year median is 786.06 vs. the industry median of 113.36, MeiraGTx Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeiraGTx Holdings's current Days Payable of 6,138.03 is 5314.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current Days Payable is 6,138.03, which is 681% above median its own 10-year median of 786.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.09, compared to a current price of €10.60 — trading 47.2% below its estimated fair value. The current Days Payable is 6,138.03, which is 681% above median its 10-year median of 786.06 and 5314.6% above the Biotechnology industry median of 113.36. MeiraGTx Holdings' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Days Payable is 6,138.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €10.60 is trading 47.2% below its estimated GF Value™ of €20.09.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
Days Payable: 6,138.03 (681% above median its 10-year median of 786.06)
GF Value™: €20.09 vs. price of €10.60 (47.2% below fair value)
Industry Position: 5314.6% above the Biotechnology median (#72 of 705)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
55GF Score
Get the complete analysis for FRA:328
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
